NLM Digital Collections

Search

Start Over Subjects Drugs, Generic -- economics ✖Remove constraint Subjects: Drugs, Generic -- economics

2. A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Author(s):
Purvis, Leigh, author
Publication:
Washington, D.C. : AARP Public Policy Institute, September 2014
Subject(s):
Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
Drugs, Generic -- economics
Federal Government
State Government
Humans
United States
United States. Food and Drug Administration.
United States.

3. Snapshots of recent state initiatives in Medicaid prescription drug cost control

Author(s):
Young, Katherine, author
Garfield, Rachel, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Cost Control -- statistics & numerical data
Cost Control -- trends
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicaid -- trends
Disclosure
Drugs, Generic -- economics
Economics, Pharmaceutical
Federal Government
Forecasting
Formularies as Topic
State Government
Humans
United States
United States. Food and Drug Administration.

4. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

5. Utilization and spending trends in Medicaid outpatient prescription drugs

Author(s):
Young, Katherine, author
Publication:
[San Francisco, California] : Henry J. Kaiser Family Foundation, February 2019
Subject(s):
Drug Utilization -- economics
Drug Utilization -- trends
Health Expenditures -- trends
Medicaid -- economics
Medicaid -- trends
Prescription Drugs -- economics
Drugs, Generic -- economics
Forecasting
Humans
United States

6. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

7. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

8. Trends in P2Y12 receptor inhibitor use and adherence after percutaneous coronary intervention, 2008-2016

Author(s):
Dayoub, Elias J., author
Seigerman, Matthew, author
Tuteja, Sony, author
Kobayashi, Taisei, author
Kolansky, Daniel, author
Giri, Jay, author
Groeneveld, Peter, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Medication Adherence -- statistics & numerical data
Percutaneous Coronary Intervention
Purinergic P2Y Receptor Antagonists -- therapeutic use
Socioeconomic Factors
Drug Costs
Drugs, Generic -- economics
Drugs, Generic -- therapeutic use
Platelet Aggregation Inhibitors -- economics
Platelet Aggregation Inhibitors -- therapeutic use
Purinergic P2Y Receptor Antagonists -- economics
Social Determinants of Health
Humans
United States

13. Rx Watchdog report: comparative measures of price change for prescription drugs and other goods

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Drug Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- trends
Drugs, Generic -- economics
Forecasting
Health Expenditures -- trends
Inflation, Economic
Humans
United States

15. Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:
Washington, D.C. : AARP Public Policy Institute, c2012
Subject(s):
Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- statistics & numerical data
Drugs, Generic -- economics
Forecasting
Pharmaceutical Preparations -- economics
Humans
United States

21. Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:
Washington, D.C. : U.S. Government Accountability Office, May 2017
Subject(s):
Drugs, Generic -- economics
Drugs, Investigational -- economics
Investigational New Drug Application -- economics
Drug Approval -- economics
Humans
United States
United States. Food and Drug Administration.

24. Generic drugs: Stakeholder views on improving FDA’s information on patents : report to congressional committees

Publication:
Washington, DC : United States Government Accountability Office, March 2023
Subject(s):
Drugs, Generic -- economics
Drug Development -- legislation & jurisprudence
Government Regulation
Legislation, Medical
Patents as Topic -- legislation & jurisprudence
Prescription Fees -- legislation & jurisprudence
United States

Refine by: